@article{ref1,
title="Homocysteine and Mobility in Older Adults",
journal="Journal of the American Geriatrics Society",
year="2010",
author="Rolita, Lydia and Holtzer, Roee and Wang, Cuiling and Lipton, Richard B. and Derby, Carol A. and Verghese, Joe",
volume="58",
number="3",
pages="545-550",
abstract="<p><b>OBJECTIVES: </b> To determine the influence of homocysteine on mobility decline in older adults.</p> <p><b>DESIGN: </b> Prospective cohort.</p> <p><b>SETTING: </b> Einstein Aging Study, community‐based aging study.</p> <p><b>PARTICIPANTS: </b> Five hundred seventy‐four older adults without dementia (mean age 80.2 ± 5.4, 61% women).</p> <p><b>MEASUREMENTS: </b> Mobility decline defined using gait velocity measurements at baseline and annual follow‐up visits. Linear mixed effects models were used to adjust for age, sex, education, and other potential confounders.</p> <p><b>RESULTS: </b> Higher homocysteine levels were associated with slower gait velocity at baseline. Adjusted for age, sex, and education, a one‐unit increase in baseline log homocysteine levels was associated with a 2.95‐cm/s faster mobility decline per year (<i>P</i>=.01) over a median follow‐up of 1.4 years. The 140 subjects in the highest quartile of homocysteine had a faster rate of mobility decline (1.75 cm/s per year faster, <i>P</i>=.01) than the 434 subjects in the lowest three quartiles of homocysteine (≤15 μmol/L). The association between homocysteine and mobility decline remained robust even after adjusting for multiple confounders and accounting for the presence of clinical gait abnormalities.</p> <p><b>CONCLUSION: </b> Higher homocysteine levels are associated with greater risk of mobility decline in community‐residing older adults.</p><p />",
language="",
issn="0002-8614",
doi="10.1111/j.1532-5415.2010.02718.x",
url="http://dx.doi.org/10.1111/j.1532-5415.2010.02718.x"
}